Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.
Author:
- Oliver SartorOSOliver Sartor
- 1 January 2004
- journal article
- Vol. 6, S3-S12
Abstract
Bone pain associated with advanced prostate and other cancers is a frequent and significant complication, and the effective management of metastatic bone disease and accompanying symptoms continues to be one of the major problems facing patients and their physicians. Treatment is in part dependent on prior treatments; usually a combination of systemic and local modalities is used because no single treatment regimen is effective for an extended period of time. The 3 radionuclides currently approved for treatment of bone pain (phosphorus-32, strontium-89, and samarium-153) are discussed in this review as viable treatment options, with emphasis on the third-generation agent in this category, samarium Sm 153 lexidronam. Clinical trial data are described that support the use of this agent in patients with hormone-refractory prostate cancer with painful metastatic bone disease, and the efficacy of and role for combination therapies are also discussed.Keywords
This publication has 30 references indexed in Scilit:
- Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancerUrology, 2004
- Radioisotopic treatment of bone pain from metastatic prostate cancer.Current Oncology Reports, 2003
- Lack of Effect of a Bisphosphonate (Pamidronate Disodium) Infusion on Subsequent Skeletal Uptake of Sm-153 EDTMPClinical Nuclear Medicine, 2002
- Therapy of metastatic bone pain.2001
- Efficacy and Safety of Repeated Samarium-153 Lexidronam Treatment in a Patient with Prostate Cancer and Metastatic Bone PainClinical Nuclear Medicine, 2000
- Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasesCancer, 2000
- Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary boneThe Prostate, 1996
- A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonateEuropean Journal of Cancer and Clinical Oncology, 1991
- Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions.Radiology, 1990
- The memorial pain assessment card. A valid instrument for the evaluation of cancer painCancer, 1987